AstraZeneca spins off autoimmune drugs into new biotech company

LONDON (Reuters) - AstraZeneca is spinning off six early-stage experimental drugs into a new $250 million standalone biotech company focused on severe autoimmune diseases.

from Reuters: Health News http://ift.tt/2BVjCjl
via IFTTT